Chat with GenHealth to automate any coding or chart task.
Name of the Procedure:
Common name: Lutetium-177 DOTATATE therapy
Technical/Medical term: Radioisotope therapy with Lutetium-177 DOTATATE (HCPCS code: A9513)
Summary
Lutetium-177 DOTATATE therapy is a specialized treatment involving a radioactive substance used to target and treat specific types of tumors, primarily neuroendocrine tumors. This medication helps to shrink tumors and relieve symptoms associated with these cancers.
Purpose
Medical conditions: Primarily used for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Goals/Outcomes: The procedure aims to reduce tumor size, slow down the progression of the disease, relieve symptoms, and potentially improve patient survival rates.
Indications
Specific symptoms/conditions: This therapy is appropriate for patients with advanced neuroendocrine tumors that express somatostatin receptors and have not responded sufficiently to other treatments.
Patient criteria: Candidates typically have confirmed diagnosis through imaging studies, possess well- to moderately-differentiated neuroendocrine tumors, and have a performance status indicating they can tolerate the treatment.
Preparation
Pre-procedure instructions:
- Fasting may be required starting a few hours before the procedure.
- Adjustments to current medications might be recommended; specific instructions will be provided by the healthcare team.
- Pre-treatment imaging and blood tests to assess general health and specific markers.
Procedure Description
- Preparation: The patient arrives at the treatment center.
- Administration: Lutetium-177 DOTATATE is administered intravenously over 30-60 minutes.
- Monitoring: The patient remains under observation for several hours post-infusion to manage any immediate side effects.
Tools/Equipment: Infusion pump, IV line, and the Lutetium-177 DOTATATE compound.
Anesthesia/Sedation: Typically, no anesthesia or sedation is required.
Duration
The infusion of Lutetium-177 DOTATATE itself takes about 30-60 minutes, with additional hours post-infusion for monitoring.
Setting
The procedure is usually performed in a hospital or specialized outpatient clinic equipped with the necessary facilities for handling radioactive substances and monitoring patients post-treatment.
Personnel
A multidisciplinary team includes:
- Nuclear medicine specialists.
- Oncologists.
- Radiologists.
- Nurses specialized in oncology and nuclear medicine.
Risks and Complications
Common risks: Nausea, vomiting, fatigue, and mild bone marrow suppression.
Rare risks: Severe kidney toxicity, liver toxicity, or blood disorders such as anemia or leukopenia. Management typically involves symptomatic treatment and close monitoring.
Benefits
Expected benefits: Reduction in tumor size, symptom relief (such as pain or hormone-related symptoms), and improved quality of life. Results may be seen within weeks to a few months post-treatment.
Recovery
Post-procedure care: Hydration is encouraged to help clear the radioactive substance from the body. Regular follow-up blood tests and imaging studies are required to monitor response and manage any side effects.
Recovery time: Varies by individual, but patients generally resume normal activities within days, with some restrictions, such as avoiding close contact with young children and pregnant women for a few days post-treatment.
Alternatives
Other treatment options: Surgery, traditional chemotherapy, other forms of radiotherapy, targeted therapies, or symptom management with hormonal treatments.
Pros and cons: Alternatives might be less invasive or have fewer immediate side effects but may not be as effective for specific tumor types or advanced stages.
Patient Experience
During the procedure: Most patients tolerate the procedure well but may feel some discomfort at the IV site.
After the procedure: Fatigue and mild nausea are common but are manageable with medications and rest. Patients are often advised to drink plenty of fluids and take it easy for a few days. Pain management protocols will be in place to ensure comfort.
Medical Policies and Guidelines
Related policies from health plans
A9513 policy automation walkthrough
Walk through the policies, prior authorization requirements, and workflow automation opportunities connected to this code.